MSD announces presentation of data on investigational use of pembrolizumab in gastric cancer

MSD, known as Merck in the United States and Canada, announced the first presentation of data on the investigational use of pembrolizumab – the company’s anti-PD-1 therapy – in PD-L1 positive, advanced gastric cancer.

Source: Pharmacy Europe - September 30, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Oncology anti-PD-1 therapy gastric cancer Latest News pembrolizumab Source Type: news